Candel Therapeutics (CADL) Total Non-Current Liabilities (2020 - 2025)

Candel Therapeutics has disclosed Total Non-Current Liabilities across 6 years of filings, most recently posting $57.7 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $57.7 million, up 42.27% year-over-year; the trailing twelve-month figure through Dec 2025 was $57.7 million (up 42.27% YoY), and the FY2025 annual result was $57.7 million, up 42.27% from the prior year.
• Total Non-Current Liabilities came in at $57.7 million for Q4 2025 at Candel Therapeutics, up from $40.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $57.7 million in Q4 2025 to a low of $5.5 million in Q3 2021.
• The 5-year median for Total Non-Current Liabilities is $26.8 million (2023), against an average of $25.2 million.
• Across the five-year window, Total Non-Current Liabilities jumped 411.57% in 2022 and decreased 21.49% in 2024, its largest moves.
• Candel Therapeutics' Total Non-Current Liabilities stood at $6.8 million in 2021, then soared by 312.19% to $28.1 million in 2022, then decreased by 1.98% to $27.5 million in 2023, then soared by 47.2% to $40.5 million in 2024, then jumped by 42.27% to $57.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $57.7 million (Q4 2025), $40.5 million (Q4 2024), and $20.9 million (Q3 2024), per Business Quant data.